This mirrors a theme that runs throughout IV nutrition therapy: there is a real difference between correcting a deficiency or supporting a well-defined biochemical pathway and selling an elective wellness infusion on the strength of mechanism alone
Predrag Sikiric, Sven Seiwerth, Zeljko Grabarevic, Petek, M., Rucman, R., Turkovic, B., Ivo Rotkvic, Vjekoslav Jagic, Duvnjak, M., Mise, S., Sanja Djacic, Jadranka Separovic, Marija Veljaca, Ahmet Sallmani, Banic, M., & Brkic, T
doi: 10.1189/jlb.0413196
Introduce gradually over several weeks
There is a lot left to understand but were hopeful we can translate these discoveries to new therapies. Several sources funded the research, including the Wilmot Cancer Institute, the American Association for Cancer Research and Breast Cancer Research Foundation, Breast Cancer Coalition of Rochester, American Cancer Society, and the National Institutes of Health
The approved-pathway comparison points remain tirzepatide (Mounjaro/Zepbound) on its own and the investigational CagriSema (cagrilintide + semaglutide)
.png)
